In 2012, Dr. Lisa Roth had just landed her dream job as a research scientist and attending physician at NewYork-Presbyterian and Weill Cornell Medicine. But her world came to a screeching halt when she discovered a swollen lymph node on her neck, and was soon diagnosed with the exact type of cancer that she had dedicated her career to studying and treating: Hodgkin Lymphoma. After that experience, Dr. Roth was more determined than ever to uncover the biology of this notoriously difficult to study cancer. Dr. Roth, now Director of Pediatric Oncology and Associate Professor in the Departments of Pediatrics, Medicine and Pathology and Laboratory Medicine at NewYork-Presbyterian and Weill Cornell Medicine, tells the story of how she and her team became the first researchers to sequence the entire Hodgkin Lymphoma genome, opening doors for precision and preventative treatment options.

For more information visit nyp.org/Advances

Monitoring patients with aneurysmal rupture for delayed cerebral ischemia was historically a numbers game. It was difficult for doctors to predict outcomes in the weeks that followed their rupture, so at-risk patients could find themselves under observation in the ICU anywhere from 7 to 21 days. Dr. Soojin Park, Medical Director of Critical Care Data Science and AI at NewYork-Presbyterian/Columbia, knew there had to be a better way to monitor patients and predict outcomes. So, relying on her background in machine learning and leveraging vast amounts of data, Dr. Park developed the potentially game-changing Continuous Monitoring Tool for Delayed Cerebral Ischemia (or COSMIC) score. The score uses machine learning, and basic patient data that can be collected with equipment available at any hospital, to detect signals that more accurately assess risk, allowing doctors to treat each neurocritical patient with targeted care - ultimately improving outcomes and patient experience.

As methods for early cancer detection improve and the number of cancer survivors rises, the innovative field of cardio-oncology has emerged to ensure that patients with chemotherapy or cancer-related cardiac dysfunction can be safely, and swiftly, treated for their cancer. Dr. Stephanie Feldman, a clinical cardiologist with focus on cardio-oncology at NewYork-Presbyterian/Weill Cornell Medicine, is one of a growing number of physicians advancing research and pushing care in this field forward with a multi-disciplinary, comprehensive approach to care. Dr. Feldman joins us to discuss the rare risks of immune checkpoint inhibitors, how genetic mutations could put patients at risk for arterial thromboembolism, and how the cardio-oncology field can optimize the course of cancer care for patients at risk for cardiovascular complications.

For more information visit nyp.org/Advances